Latest Life Sciences News

Page 4 of 21
Microba Life Sciences delivered a mixed FY26, with overall revenue slipping 5.8% to $14.76 million and a statutory loss widening 38.7% to $20.7 million. The company’s strategic pivot to core microbiome testing paid off with a 92% surge in core testing revenue and record test volumes in Australia and the UK. Despite the headline loss, underlying loss improved 11% thanks to cost cuts and AI-driven efficiencies. Microba is gearing up for the October launch of its GI Navigator diagnostic and targeting cash flow break-even on a run-rate basis in calendar 2027.
Ada Torres
Ada Torres
31 Aug 2026
Atomo Diagnostics lifted revenue 41% to AUD 5.33 million for FY26, cutting its loss by 29% to AUD 3.51 million, driven by HIV self-testing growth and a key US partnership. Leadership changes signal a strategic pivot as the company eyes global expansion.
Ada Torres
Ada Torres
31 Aug 2026
Thorney Technologies Ltd posted a $16.4 million net loss for FY2026, deepening from last year, as it continued to simplify its portfolio and execute a substantial share buyback program.
Victor Sage
Victor Sage
28 Aug 2026
PYC Therapeutics strengthened its financial footing with a $600 million capital raise and made notable clinical progress across four RNA therapeutic programs targeting genetic diseases.
Ada Torres
Ada Torres
28 Aug 2026
Patrys has cleared a key regulatory hurdle with Human Research Ethics Committee approval for its Phase 1A clinical trial of RLS-2202, aiming to start dosing healthy volunteers this quarter.
Ada Torres
Ada Torres
28 Aug 2026
Clinuvel Pharmaceuticals marked its tenth consecutive profit with stable revenues and rising cash reserves, while accelerating U.S. expansion including a Nasdaq uplisting and potential ASX delisting.
Victor Sage
Victor Sage
27 Aug 2026
Genetic Signatures (ASX: GSS) and Microba Life Sciences (ASX: MAP) are in early talks about merging to form a larger infectious disease diagnostics entity, combining rapid pathogen detection with microbiome profiling. The proposed group would have FY2026 pro forma revenue of around A$29 million and a stronger financial footing.
Ada Torres
Ada Torres
26 Aug 2026
Atomo Diagnostics has appointed Dr Cheri Walker as interim CEO, replacing founder John Kelly who steps down after 15 years. The leadership change aligns with the company's shift towards commercial growth in the US and Europe.
Ada Torres
Ada Torres
19 Aug 2026
HealthCo Healthcare & Wellness REIT delivered strong FY26 results with 100% rent collection and solid portfolio metrics, while progressing alternative lease arrangements for its Healthscope hospital portfolio.
Eva Park
Eva Park
18 Aug 2026
Vita Life Sciences delivered a robust first half in 2026 with revenue up 6.1% to A$48.3 million and net profit after tax rising 14.9% to A$5.54 million. The company declared a higher interim dividend, reflecting improved margins and regional market momentum.
Ada Torres
Ada Torres
17 Aug 2026
Vitrafy Life Sciences reported an 80% revenue surge and halved its net loss, buoyed by US military validation and major blood network partnerships. A $32 million capital raise fuels its US commercial expansion and manufacturing scale-up.
Victor Sage
Victor Sage
4 Aug 2026
Synertec has locked in a $4 million contract to upgrade AGL’s national SCADA system, reinforcing its foothold in critical infrastructure technology as it forecasts up to 50% revenue growth in FY27.
Maxwell Dee
Maxwell Dee
30 July 2026

Browse the archive

Full archive